Careers in Israel
Careers in USA
Board of Directors
Scientific Advisory Board
Johns Hopkins University
Mount Sinai Hospital
Annual and Quarterly Reports
Therapeutic product discovery
In the information age
The next wave in immuno-oncology
Apr 17, 2018
Preclinical Data Presented by Bayer at AACR Highlights BAY 1905254, formerly the CGEN-15001T Program, Efficacy in Cancer Immunotherapy
Apr 02, 2018
Compugen Announces Exclusive License Agreement with MedImmune for the Development of Bi-Specific and Multi-Specific Antibody Products
Our optimized process for predictive discovery of novel drug targets
Discovery & development of first-in-class monoclonal antibody therapeutics
Compugen, FROM CODE TO CURE
CGEN-15029 is the internal designation for PVRIG, a novel B7/CD28-like immune checkpoint target candidate discovered by...
CGEN-15137 is the internal designation for TIGIT, an immune checkpoint in the B7/CD28 family which has recently gained broad...
CGEN-15001T is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15001T is expressed in various subpopulations of immune cells...
CGEN-15001 is our lead program for autoimmune diseases. It is a first-in-class therapeutic candidate of a novel inhibitory checkpoint pathway, with the potential to restore...
Apr 02, 2018
MedImmune License Agreement
Mar 13, 2018
Compugen Presentation at the Cowen and Company 38th Annual Health Care Conference
Feb 21, 2018
Compugen Fourth Quarter and Full Year 2017 Earnings Conference Call
In August 2013, Compugen entered into a collaboration and license agreement with Bayer HealthCare ...
In March 2018, Compugen entered into an exclusive license agreement with MedImmune, the global biologics research and ...
Click here for more info about partnering with Compugen